Allogene Therapeutics Inc.’s recent filing unveils that its Director Mayo Stephen unloaded Company’s shares for reported $42855.0 on Aug 07. In the deal valued at $4.29 per share,10,000 shares were sold. As a result of this transaction, Mayo Stephen now holds 25,328 shares worth roughly $ 0.1 million.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Then, Bhavnagri Veer sold 3,000 shares, generating $20,550 in total proceeds. Upon selling the shares at $6.85, the General Counsel now owns 577,677 shares.
Before that, Bhavnagri Veer sold 3,000 shares. Allogene Therapeutics Inc. shares valued at $21,120 were divested by the General Counsel at a price of $7.04 per share. As a result of the transaction, Bhavnagri Veer now holds 580,677 shares, worth roughly $2.3 million.
PT values the company’s stock at a premium of 85.86 to its Tuesday closing price.
Price Performance Review of ALLO
On Tuesday, Allogene Therapeutics Inc. [NASDAQ:ALLO] saw its stock fall -2.22% to $3.96. On the same session, the stock had its day’s lowest price of $3.915, but rose to a high of $4.18. Over the last five days, the stock has gained 4.76%. Allogene Therapeutics Inc. shares have fallen nearly -37.04% since the year began. Nevertheless, the stocks have fallen -72.15% over the past one year. While a 52-week high of $15.56 was reached on 01/27/23, a 52-week low of $3.70 was recorded on 08/21/23. SMA at 50 days reached $4.63, while 200 days put it at $6.00. A total of 1.51 million shares were traded, compared to the trading of 3.42 million shares in the previous session.
Levels Of Support And Resistance For ALLO Stock
The 24-hour chart illustrates a support level at 3.86, which if violated will result in even more drops to 3.75. On the upside, there is a resistance level at 4.12. A further resistance level may holdings at 4.28. The Relative Strength Index (RSI) on the 14-day chart is 42.07, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.05, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 45.83%. Stochastics %K at 72.32% indicates the stock is a holding.
How much short interest is there in Allogene Therapeutics Inc.?
A steep rise in short interest was recorded in Allogene Therapeutics Inc. stocks on Aug 14, 2023, dropping by -8.49 million shares to a total of 32.77 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 41.26 million shares. There was a decline of -25.91%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 28.83% of the overall stock float, the days-to-cover ratio (short ratio) fell to 15.22.
Allogene Therapeutics Inc. [ALLO] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 24,917,955 shares, or roughly 14.87% of the outstanding ALLO shares. In other words, the investor’s shares have risen by 23,548,101 from its previous 13-F filing of 1369854.0. Additionally, SSgA Funds Management, Inc. increased 3.26% of its stake after which the total value it holdings stand at $42,054,655, while The Vanguard Group, Inc. added 2.77% of its stake to hold $36.53 million in the firm. Over the last quarter, BlackRock Fund Advisors sold -275,090 shares of Allogene Therapeutics Inc., while PRIMECAP Management Co. sold -132,300 shares. At present, Woodline Partners LP is holding 5,313,500 shares valued at $26.35 million. T. Rowe Price Associates, Inc. owned 5,292,326 shares of the company at the time of its most recent 13F filing, worth $26.25 million.
According to FactSet, Allogene Therapeutics Inc.’s share price will average $16.13 in the next year, based on opinions of analysts polled by the firm. This is up nearly 270.37 percent from its previous closing price of $4.05. Analysts expect Allogene Therapeutics Inc. stock to reach the higher price of $35.00, while the lowest price estimate is $5.00. However, 19 analysts have rated ALLO stock as an Overweight in their predictions for 2023.